Wikipedia

User:Mr. Ibrahem/Azilsartan

< User:Mr. Ibrahem

Mr. Ibrahem/Azilsartan
Clinical data
Trade namesEdarbi, Azilva
Other namesAzilsartan medoxomil, TAK-536, TAK-491
AHFS/Drugs.comMonograph
MedlinePlusa611028
License data
Routes of
administration		By mouth
Drug classAngiotensin II receptor blocker[1]
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability60%
MetabolismCYP2C9
Onset of actionWithin 2 wks[2]
Elimination half-life11 hrs
Excretion55% feces, 42% urine
Identifiers
  • 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-1H-benzimidazole-7-carboxylic acid
Chemical and physical data
FormulaC25H20N4O5
Molar mass456.458 g·mol−1
3D model (JSmol)
  • CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O
  • InChI=InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32) ☒N
  • Key:KGSXMPPBFPAXLY-UHFFFAOYSA-N ☒N

  • as medoxomil: InChI=1S/C30H24N4O8 /c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
  • Key:QJFSABGVXDWMIW-UHFFFAOYSA-N
 ☒NcheckY (what is this?)  (verify)

Azilsartan, sold under the brand name Edarbi, is a medication used to treat high blood pressure.[1][3] Other uses may include diabetic kidney disease and heart failure.[2] It is taken by mouth.[2] Effects generally occur within 2 weeks.[2]

Common side effects include diarrhea and dizziness.[1][3] Other side effects may include angioedema, low blood pressure, and kidney problems.[2] Use in pregnancy may harm the baby.[4] It is an angiotensin II receptor blocker.[1]

Azilsartan was approved for medical use in the United States and Europe in 2011.[1][3] In the United Kingdom 4 weeks costs the NHS less than £20 as of 2021.[5] This amount in the United States is about 160 USD.[6]

References

edit
  1. ^ a b c d e f "Edarbi- azilsartan kamedoxomil tablet". DailyMed. 26 July 2019. Archived from the original on 7 February 2019. Retrieved 9 March 2020.
  2. ^ a b c d e f "Azilsartan Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 17 January 2022.
  3. ^ a b c d "Edarbi EPAR". European Medicines Agency (EMA). 18 May 2018. Archived from the original on 24 March 2020. Retrieved 9 March 2020.
  4. ^ "Azilsartan medoxomil (Edarbi) Use During Pregnancy". Drugs.com. Archived from the original on 26 November 2020. Retrieved 17 January 2022.
  5. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 189. ISBN 978-0857114105.
  6. ^ "Azilsartan Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 1 November 2016. Retrieved 17 January 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Azilsartan&oldid=1099132678"